(Public, NASDAQ:TSRO)   Watch this stock  
Find more results for MERCK SHARP & DOHME CORP
-1.87 (-4.43%)
After Hours: 40.34 -0.01 (-0.02%)
Oct 6, 4:37PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 38.05 - 42.20
52 week 23.00 - 66.95
Open 42.01
Vol / Avg. 435,572.00/631,150.00
Mkt cap 1.69B
P/E     -
Div/yield     -
EPS -5.15
Shares 40.03M
Beta 1.49
Inst. own 114%
Nov 3, 2015
Q3 2015 TESARO Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 1, 2015
TESARO Inc at Leerink Partners Immuno-Oncology Roundtable
Sep 10, 2015
TESARO Inc at Robert W Baird and Co Health Care Conference
Sep 10, 2015
TESARO Inc at Citi Biotech Conference
Aug 6, 2015
Q2 2015 TESARO Inc Earnings Call - Webcast
Aug 6, 2015
Q2 2015 TESARO Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -63.10% -85.62%
Return on average equity -103.40% -138.35%
Employees 108 -
CDP Score - -


1000 Winter St Ste 3300
WALTHAM, MA 02451-1230
United States - Map
+1-339-9700900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. President, Chief Operating Officer, Director
Age: 52
Bio & Compensation  - Reuters
Leon O. Moulder Jr. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Timothy R. Pearson Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Joseph L. Farmer Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Martin Huber M.D. Senior Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
James O. Armitage M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Garry A Nicholson Independent Director
Bio & Compensation  - Reuters
Arnold L. Oronsky Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Beth C. Seidenberg M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters